Peer-reviewed original articles

34. Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnström H, Mattsson JSM, Pontén V, Eltahir M, Mangsbo S, Isaksson J, Jirström K, Kärre K, Carbone E, Leandersson K, Mezheyeuski A, Pontén F, Lindskog C, Botling J, Micke P.  Extending the immune phenotypes of lung cancer: Oasis in the desert. In press Journal of Thoracic Oncology. 

33. Georganaki M, Ramachandran M, Tuit S, Gonzalo Núñez N, Karampatzakis A, Grammatiki Fotaki G, van Hooren L, Huang H, Lugano R, Ulas T, Kaunisto A, Holland EC, Ellmark P, Mangsbo S, Schultze J, Essand M, Tugues S, Dimberg A. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-backmechanism that reduces the response to CD40-stimulating immunotherapy. In press Oncoimmunology. 

32. Ibarra C, Karlsson M, Codeluppi S, Varas-Godoy M, Zhang S, Louhivuori L, Mangsbo S, Hosseini A, Soltani N, Kaba R, Kalle Lundgren T, Hosseini A, Tanaka N, Oya M, Wiklund P, Miyakawa A, Uhlén P. BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling.Mol Oncol. 2019 Feb;13(2):202-211

31. EAK Fletcher, W van Maren, R Cordfunke, J Dinkelaar, JDC Codee, G van der Marel, CJM Melief, F Ossendorp, JW Drijfhout, SM Mangsbo. Formation of immune-complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently-linked peptides in an ex-vivo blood loop system. J Immunol. 2018 Jul 1;201(1):87-97018

30. Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW.Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses.Mol Immunol. 2018 Jan;93:115-124

29. Irenaeus S, Schiza A, Mangsbo SM, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ. Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.Oncotarget. 2017 Jul 31;8(45):78573-78587.

28. Fletcher EAK, Eltahir M, Lindqvist F, Rieth J, Törnqvist G, Leja-Jarblad J, Mangsbo SM. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.Int Immunopharmacol. 2018 Jan;54:1-11. 

27. Schiza A, Wenthe J, Mangsbo SM, Eriksson E, Nilsson A, Tötterman TH, Loskog A, Ullenhag G. Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.J Transl Med. 2017 Apr 20;15(1):79. doi: 10.1186/s12967-017-1182-z.

26. Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich LC, Christiansson L, Karlsson H, Ullenhag G, Mangsbo SM, Dimberg A, Alemany R, Loskog A. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.Gene Ther. 2017 Feb;24(2):92-103. doi: 10.1038/gt.2016.80. Epub 2016 Dec 1.

25. van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SMLocal checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.

24. van Hooren L, Georganaki M, Huang H, MangsboSM, Dimberg A. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget. 2016 Jul 1;7(31):50277-50289. doi: 10.18632/oncotarget.10364.

23. Loskog A, Maleka A, Mangsbo SM, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH, Ullenhag G. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.Br J Cancer. 2016 Apr 12;114(8):872-80. doi: 10.1038/bjc.2016.42. Epub 2016 Mar 31.

22. Vogel S, Grabski E, Buschjäger D, Klawonn F, Döring M, Wang J, Fletcher E, Bechmann I, Witte T, Durisin M, Schraven B, Mangsbo SM, Schönfeld K, Czeloth N, Kalinke U.Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308.

21. Christiansson L, Söderlund S, Mangsbo SM, Hjorth-Hansen H, Höglund M, Markevärn B, Richter J, Stenke L, Mustjoki S, Loskog AS and Olsson-Strömberg U.The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses.Mol Cancer Ther. 2015 Mar 11.

20. Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SMThe cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention. J Neuroimmunology 2014 15;277(1-2):153-9

19. Mangsbo SM, Broos S, Fletcher E, Veitonmaki N, Furebring C, Dahlen E, Norlen P, Lindstedt M, Totterman TH, Ellmark P. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity.Clin Cancer Res. 2015 Mar 1;21(5):1115-26.

18. Yilmaz-Elis AS, Ramirez JM, Asmawidjaja P, van der Kaa J, Mus AM, Brem MD, Claassens JW, Breukel C, Brouwers C, Mangsbo SM, Boross P, Lubberts E, Verbeek JS. FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis.J Immunol. 2014 Jun 15;192(12):5540-7

17. Christiansson L, Mustjoki S, Simonsson B, Olsson-Strömberg U, Loskog A, Mangsbo SMThe use of Multiplex Platforms for Absolute and Relative Protein Quantification of Clinical Material. Accepted in EuPA Open Proteomics 2014, online version available on the journal’s website.

16. Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SMA hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells. J Immunother. 2014 Apr;37(3):155-62.

15. Liljenfeldt L, Dieterich L, Dimberg A, Mangsbo SM, Loskog A.CD40L Gene Therapy Tilts the Myeloid Cell Profile and Promotes Infiltration of Activated T Lymphocytes. Cancer Gene Ther. 2014 Mar;21(3):95-102. contributed equally as last authors

14. Sandin L, Eriksson F, Ellmark P, Loskog A, Tötterman TH, Mangsbo SMLocal CTLA-4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.Oncoimmunology 2014 Jan 1;3(1):e27614.

13. Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunol Res 2014 Jan: 2;80.

12. Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog AS.T cell responses after hematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.Immunology. 2013 Oct;140(2):211-9.

11. Sharp PE, Martin-Ramirez J, Mangsbo SM, Boross P, Pusey CD, Touw IP, Cook HT, Verbeek JS, Tarzi RM. FcγRIIb on myeloid cells and intrinsic renal cells rather than B cells protects from nephrotoxic nephritis.J Immunol. 2013 Jan 1;190(1):340-8.

10. van Montfoort N, 't Hoen PA, Mangsbo SM, Camps MG, Boross P, Melief CJ, Ossendorp F, Verbeek JS. Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.J Immunol. 2012 Jul 1;189(1):92-101

9. van Montfoort NMangsbo SM, Camps MGM, van Maren WWC, Verhaart IEC, Waisman A, Drijfhout JW, Melief CJM, Verbeek JS, Ossendorp F. Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo.Eur J Immunol. 2012 Mar;42(3):598-606     contributed equally as first authors

8. Sharp PE, Martin-Ramirez J, Boross P, Mangsbo SM, Reynolds J, Moss J, Pusey CD, Cook HT, Tarzi RM, Verbeek JS. Increased incidence of anti-GBM disease in Fcgamma receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone.Mol Immunol. 2012 Feb;50(1-2):49-56.

7. Lindqvist CA, Christiansson LH, Thörn I, Mangsbo S, Paul-Wetterberg G, Sundström C, Tötterman TH, Simonsson B, Enblad G, Frisk P, Olsson-Strömberg U, Loskog AS.Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.Immunology. 2011 Jul;133(3):296-306

6. Malmström P‐U, Loskog A, Lindqvist C, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH. AdCD40L Immunogene Therapy for Bladder Carcinoma The First Phase I/IIa Trial. Clin Cancer Res2010 Jun 15;16(12):3279‐87.

5.Mangsbo SM, Sandin L, Anger K, Korman A, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA4 or PD1 blockade with CpG therapy.J Immunother. 2010 Apr;33 (3):225‐35.

4. Lund T, Mangsbo SM, Scholz H, Tötterman TH, Korsgren O, Foss A. Resolvin E1 reduces inflammation in human pancreatic islets in vitro.Exp Clin Endocrinol Diabetes. 2010 Apr;118(4):237‐44.

3.Mangsbo SM, Sanchez J, Anger K, Lambris JD, Ekdahl KN, Loskog AS, Nilsson B, Tötterman TH. Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.J Immunol.2009 Nov 15;183 (10):6724‐32.

2. Eriksson F, Tzagozis P, Lundberg K, Parsa K, Mangsbo SM, Persson MAA, Harris RA, Pisa P. TumorSpecific Bacteriophages Induce Tumor Destruction through Activation of TumorAssociated Macrophages. J Immunol. 2009 Mar 1;182(5): 3105-11.

1. Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T cell immunity. J Immunotherapy 2008 Jan; 31(1):34-42.

Review articles

5. Eltahir M, Persson H, Mangsbo STumor localized agonistic anti-CD40 therapy and beyond.Expert Opin Biol Ther. 2020 Jan 10:1-3.

4. Ellmark P, Mangsbo SM, Furebring C, Norlén P, Tötterman TH. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.Cancer Immunol Immunother. 2017 Jan;66(1):1-7. doi: 10.1007/s00262-016-1909-3. Epub 2016 Oct 6. Review

3. Ellmark P, Mangsbo SM, Furebring C, Tötterman TH, and Norlén P. Kick-starting the cancer-immunity cycle by targeting CD40.Oncoimmunology 2015.

2. Sandin LC, Tötterman TH, Mangsbo SMLocal immunotherapy using agonistic CD40 antibodies effectively inhibits experimental bladder cancer. Oncoimmunology 2014.

1.Mangsbo SM.Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs.BJU Int. 2011 Oct;108(7):1214-5.

Recent Peer-reviewed conference contributions 

Kyriaki I and Mangsbo SM. Abstract A137: The innate/adaptive immune response triggered in response to local immunotherapy of orthotopically growing bladder cancer tumors. DOI: 10.1158/2326-6074.CRI CIMT EATI AACR18-A137 Published February 2019

Dimberg A, Karampatzakis A, Tuit S, Ramachandran M, Fotaki G, van Hooren L, Huang H, Lugano R, Aura K, Ellmark P, Mangsbo SM, Schultze JL, Essand M and Georganaki M. Abstract A128: Tumor endothelial cells say IDO to CD40-stimulating immunotherapy. DOI: 10.1158/2326-6074.CRI CIMT EATI AACR18-A128 Published February 2019

Drijfhout JW, Fletcher E, Leja-Jarblad J, Kerzeli I, Cordfunke R, Tornqvist G, Lindqvist F, Hultqvist G, Valentijn R, Ladjervardi S, Haggman M, Ullenhag G and Mangsbo SM. Abstract 5638: A tetanus-way of improving synthetic long peptide tumor vaccination. DOI: 10.1158/1538-7445.AM2018-5638 Published July 2018

Senast uppdaterad: 2022-01-12